title: Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
abstract: The aim of our study was to determine whether, in patients with familiar combined hyperlipoproteinemia (FCH), ciprofibrate produces changes in paraoxonase, which acts as an antioxidant. A further aim was to estimate changes in serum levels of apolipoproteins, especially in apolipoprotein (apo) A-I and apoC-III. One of the mechanisms of action of fibrates is the activation apo A-I biosynthesis and the inhibition of apoC-III production. It is performed in the liver through peroxisome proliferator activated receptor (PPAR)-alpha activity. We found that ciprofibrate administration enhanced production of apoA-I and paraoxonase transport capacity. Decreases in paraoxonase during ciprofibrate treatment were not statistically significant but increases in serum levels of apoA-I were statistically significant. Levels of apoC-III were decreased, which suggests that ciprofibrate belongs in the group of fibrates that influences lipoprotein metabolism through PPAR-alpha activity.
authors.affiliation: Biochemistry Department, Regional Hospital Polyclinic, Zvolen, Slovak Republic.
authors.forename: J
authors.initials: J
authors.lastname: Turay
authors.forename: V
authors.initials: V
authors.lastname: Grniaková
authors.forename: J
authors.initials: J
authors.lastname: Valka
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D053305:Apolipoprotein C-III; D001053:Apolipoproteins / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood; D001056:Apolipoproteins C / Q000097:blood; D001057:Apolipoproteins E / Q000097:blood; D043303:Aryldialkylphosphatase; D008076:Cholesterol, HDL / Q000097:blood; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004950:Esterases / Q000097:blood*; D005260:Female; D058607:Fibric Acids; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000097:blood* / Q000188:drug therapy* / Q000201:enzymology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D016632:Apolipoprotein A-I; D053305:Apolipoprotein C-III; D001053:Apolipoproteins; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D004950:Esterases; D043303:Aryldialkylphosphatase; C019304:ciprofibrate